Market Overview

UPDATE: BMO Capital Markets Initiates Intercept Pharmaceuticals at Outperform on Outlook

Related ICPT
Intercept Presents New Data Analyses on Non-Invasive Liver Testing From FLINT Trial of Obeticholic Acid in Nonalcoholic Steatohepatitis at AASLD 2015
Intercept Presents New Primary Biliary Cholangitis Data at AASLD 2015
Novo Nordisk's First Diabetes Pill Could Be A $10-20B Super-Blockbuster (Seeking Alpha)

BMO Capital Markets initiated coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with an Outperform rating and a $31 price target.

BMO Capital Markets said, "Our positive outlook is supported by a proprietary platform of bile acid analogs, a deep pipeline of clinical candidates, and a lead opportunity in Primary Biliary Cirrhosis (PBC), a rare orphan disease supporting a $500 million–$1 billion opportunity. With phase 3 data for lead bile acid analog OCA (INT-747) expected by mid-2013, phase 2 data in PBC is compelling, in our opinion, and should support a clear benefit in patients failing current standard bile acid therapy with ursodiol (URSO)."

Intercept Pharmaceuticals closed at $18.75 on Friday.

Latest Ratings for ICPT

Nov 2015Leerink SwannMaintainsMarket Perform
Aug 2015Morgan StanleyInitiates Coverage onUnderweight
May 2015BarclaysInitiates Coverage onOverweight

View More Analyst Ratings for ICPT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (ICPT)

Get Benzinga's Newsletters